Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept for CNV in Angioid Streaks
NCT02573038Phase 2Withdrawn
- Sponsor
- Hospices Civils de Lyon
- Start
- Feb 2016
- Primary completion
- May 2018
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
01
Overview
Phase 2, open-label, single-arm trial of aflibercept in choroidal neovascularization (CNV), sponsored by Hospices Civils de Lyon. Primary endpoint: Mean change in best corrected visual acuity at 52 weeks. Planned start Feb 2016; status: withdrawn.
02
Drugs
aflibercept
03
Conditions
choroidal neovascularization (CNV)
Beyond the preview
Go deeper on NCT02573038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02573038.